• Malignant mesothelioma: Phase II (completed- NCT02860286)• Metastatic prostate cancer: Phase I (recruiting, NCT04179864, NCT04846478)• Solid tumors harboring an ARID1A mutation: Phase II (not yet recruiting- NCT05023655)• Refractory INI1-Negative tumors or synovial sarcoma: Phase I (completed- NCT02601937)• Peripheral nerve sheath tumor: Phase II (recruiting- NCT04917042)• Metastatic melanoma: Phase II (recruiting- NCT04557956)• Advanced colorectal carcinoma, advanced soft-tissue sarcoma, advanced pancreatic adenocarcinoma: Phase II (recruiting- NCT04705818). This evidence concerns the gene ARID1A and Familial prostate cancer.